• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Divis Labs gets US FDA import alert

financialexpressMarch 22, 2017

Tag: Import Alert , FDA

US FDA has issued an Import Alert 66-40 to Divis Laboratories for its Unit-II at Visakhapatnam, Andhra Pradesh. However, the US agency has exempted 10 products manufactured in the plant from the alert list.

The exempted products are Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium, Raltegravir potassium, Atovaquone, Chloropurine, BOC core succinate and 2,4-wing active ester.

The company has announced that it is working with third party consultants to address the concerns of the USFDA and meet the compliance requirements.

Previous:Bausch + Lomb and Nicox Announce PDUFA Date for Novel Glaucoma Candidate Latanoprostene Bunod

Next:Merck Accelerator hits new peak of applications

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Divis Labs gets US FDA import alert | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Tobramycin base( FDA)

Tobramycin base( FDA)
Adriacin HCL (FDA)

Adriacin HCL (FDA)
Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers
Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
Simvastatin (FDA)

Simvastatin (FDA)
Ifosfamide (FDA)

Ifosfamide (FDA)
Mesnaum (FDA)

Mesnaum (FDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
Clozapine (FDA)

Clozapine (FDA)
99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service